WO2014118705A1 - Procédé de traitement des troubles minéraux et osseux de la maladie rénale chronique en utilisant des antagonistes de la sclérostine - Google Patents

Procédé de traitement des troubles minéraux et osseux de la maladie rénale chronique en utilisant des antagonistes de la sclérostine Download PDF

Info

Publication number
WO2014118705A1
WO2014118705A1 PCT/IB2014/058619 IB2014058619W WO2014118705A1 WO 2014118705 A1 WO2014118705 A1 WO 2014118705A1 IB 2014058619 W IB2014058619 W IB 2014058619W WO 2014118705 A1 WO2014118705 A1 WO 2014118705A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
sclerostin
patient
antigen
seq
Prior art date
Application number
PCT/IB2014/058619
Other languages
English (en)
Inventor
Michaela Kneissel
Uwe Junker
Ronenn Roubenoff
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of WO2014118705A1 publication Critical patent/WO2014118705A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

La présente invention concerne un procédé de traitement des troubles minéraux et osseux (TMO) de la maladie rénale chronique (MRC), y compris de patients ayant un diagnostic de TMO-MCR, par exemple, des patients MRC stade 3-5 (par exemple, des patients MRC-5D) ayant une ostéodystrophie rénale (ODR), de préférence une maladie osseuse adynamique (ABD), par antagonisation de l'expression, de la sécrétion, de la signalisation et/ou de la fonction de la sclérostine, par exemple, en utilisant un anticorps anti-sclérostine ou un fragment de liaison de l'antigène de celui-ci (par exemple, l'anticorps 1).
PCT/IB2014/058619 2013-01-31 2014-01-28 Procédé de traitement des troubles minéraux et osseux de la maladie rénale chronique en utilisant des antagonistes de la sclérostine WO2014118705A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361758966P 2013-01-31 2013-01-31
US61/758,966 2013-01-31

Publications (1)

Publication Number Publication Date
WO2014118705A1 true WO2014118705A1 (fr) 2014-08-07

Family

ID=50391221

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/058619 WO2014118705A1 (fr) 2013-01-31 2014-01-28 Procédé de traitement des troubles minéraux et osseux de la maladie rénale chronique en utilisant des antagonistes de la sclérostine

Country Status (1)

Country Link
WO (1) WO2014118705A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108291258A (zh) * 2015-06-04 2018-07-17 Emv梅斯有限公司 诊断和治疗mers相关肾病
WO2019227087A3 (fr) * 2018-05-25 2020-01-02 The Trustees Of Columbia University In The City Of New York Biomarqueurs du type d'ostéodystrophie rénale
WO2021091868A1 (fr) * 2019-11-04 2021-05-14 Regeneron Pharmaceuticals, Inc. Modèle de rongeur à densité minérale osseuse accrue

Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
WO2000032773A1 (fr) 1998-11-27 2000-06-08 Darwin Discovery Ltd. Compositions et methodes d'augmentation de la mineralisation de la substance osseuse
US20030229041A1 (en) 2002-03-01 2003-12-11 Sutherland May S. Kung Methods to increase or decrease bone density
WO2003106657A2 (fr) 2002-06-14 2003-12-24 Stowers Institute For Medical Research Sequences nucleotidiques et sequences d'acides amines wise/sost
US6703199B1 (en) 1997-06-12 2004-03-09 Research Corporation Technologies, Inc. Artificial antibody polypeptides
WO2005003158A2 (fr) 2003-06-16 2005-01-13 Celltech R & D, Inc. Compositions et methodes d'augmentation de la mineralisation osseuse
WO2005014650A2 (fr) 2003-06-16 2005-02-17 Celltech R & D, Inc. Anticorps specifiques de la sclerostine et methodes permettant d'accroitre la mineralisation osseuse
WO2006102070A2 (fr) 2005-03-18 2006-09-28 Enzo Biochem, Inc. Sclerostine et inhibition de la signalisation par le wnt, et formation osseuse
WO2006119107A2 (fr) 2005-05-03 2006-11-09 Ucb Pharma S.A. Agents de fixation
WO2006119062A2 (fr) 2005-05-03 2006-11-09 Ucb Pharma S.A. Epitopes
WO2008016404A2 (fr) * 2006-07-31 2008-02-07 Zelos Therapeutics, Inc. Analogues de l'hormone parathyroïdienne et leurs procédés d'utilisation
WO2008061013A2 (fr) 2006-11-10 2008-05-22 Amgen Inc. Diagnostic et thérapie basés sur des anticorps
WO2008115732A2 (fr) 2007-03-20 2008-09-25 Eli Lilly And Company Anticorps antisclérostine
WO2008133722A2 (fr) 2006-11-10 2008-11-06 Ucb Pharma S.A. Anticorps et diagnostics
WO2009039175A2 (fr) 2007-09-17 2009-03-26 Amgen Inc. Procédé pour inhiber la résorption osseuse
WO2009047356A1 (fr) 2007-10-12 2009-04-16 Novartis Ag Compositions et procédés pour l'utilisation d'anticorps contre la sclérostine
WO2009079471A1 (fr) 2007-12-14 2009-06-25 Amgen Inc. Procédé de traitement d'une fracture osseuse à l'aide d'anticorps anti-sclérostine
US20100028335A1 (en) 2007-02-02 2010-02-04 Novartis Ag Compositions and Methods to Treat Bone Related Disorders
WO2010115932A1 (fr) * 2009-04-08 2010-10-14 Novartis Ag Combinaison pour traitement de perte osseuse

Patent Citations (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6180370B1 (en) 1988-12-28 2001-01-30 Protein Design Labs, Inc. Humanized immunoglobulins and methods of making the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5585089A (en) 1988-12-28 1996-12-17 Protein Design Labs, Inc. Humanized immunoglobulins
US5693762A (en) 1988-12-28 1997-12-02 Protein Design Labs, Inc. Humanized immunoglobulins
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6703199B1 (en) 1997-06-12 2004-03-09 Research Corporation Technologies, Inc. Artificial antibody polypeptides
WO2000032773A1 (fr) 1998-11-27 2000-06-08 Darwin Discovery Ltd. Compositions et methodes d'augmentation de la mineralisation de la substance osseuse
US7758858B2 (en) 1998-11-27 2010-07-20 Darwin Discovery Ltd. Antibodies associated with alterations in bone density
US7578999B2 (en) 1998-11-27 2009-08-25 Celltech R & D, Inc. Antibodies specific for sclerostin
US20030229041A1 (en) 2002-03-01 2003-12-11 Sutherland May S. Kung Methods to increase or decrease bone density
US20080227138A1 (en) 2002-03-01 2008-09-18 Celltech R & D, Inc. Methods to Increase or Decrease Bone Density
WO2003106657A2 (fr) 2002-06-14 2003-12-24 Stowers Institute For Medical Research Sequences nucleotidiques et sequences d'acides amines wise/sost
WO2005003158A2 (fr) 2003-06-16 2005-01-13 Celltech R & D, Inc. Compositions et methodes d'augmentation de la mineralisation osseuse
WO2005014650A2 (fr) 2003-06-16 2005-02-17 Celltech R & D, Inc. Anticorps specifiques de la sclerostine et methodes permettant d'accroitre la mineralisation osseuse
US7381409B2 (en) 2003-06-16 2008-06-03 Celltech R&D, Inc. Antibodies specific for sclerostin and methods of screening and use therefor
WO2006102070A2 (fr) 2005-03-18 2006-09-28 Enzo Biochem, Inc. Sclerostine et inhibition de la signalisation par le wnt, et formation osseuse
WO2006119062A2 (fr) 2005-05-03 2006-11-09 Ucb Pharma S.A. Epitopes
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US7872106B2 (en) 2005-05-03 2011-01-18 Amgen Inc. Sclerostin-binding antibodies
WO2006119107A2 (fr) 2005-05-03 2006-11-09 Ucb Pharma S.A. Agents de fixation
WO2008016404A2 (fr) * 2006-07-31 2008-02-07 Zelos Therapeutics, Inc. Analogues de l'hormone parathyroïdienne et leurs procédés d'utilisation
WO2008133722A2 (fr) 2006-11-10 2008-11-06 Ucb Pharma S.A. Anticorps et diagnostics
WO2008061013A2 (fr) 2006-11-10 2008-05-22 Amgen Inc. Diagnostic et thérapie basés sur des anticorps
US20100028335A1 (en) 2007-02-02 2010-02-04 Novartis Ag Compositions and Methods to Treat Bone Related Disorders
US7744874B2 (en) 2007-03-20 2010-06-29 Eli Lilly And Company Anti-sclerostin antibodies
WO2008115732A2 (fr) 2007-03-20 2008-09-25 Eli Lilly And Company Anticorps antisclérostine
WO2009039175A2 (fr) 2007-09-17 2009-03-26 Amgen Inc. Procédé pour inhiber la résorption osseuse
WO2009047356A1 (fr) 2007-10-12 2009-04-16 Novartis Ag Compositions et procédés pour l'utilisation d'anticorps contre la sclérostine
US7879322B2 (en) 2007-10-12 2011-02-01 Novartis Ag Compositions and methods for use for antibodies against sclerostin
WO2009079471A1 (fr) 2007-12-14 2009-06-25 Amgen Inc. Procédé de traitement d'une fracture osseuse à l'aide d'anticorps anti-sclérostine
WO2010115932A1 (fr) * 2009-04-08 2010-10-14 Novartis Ag Combinaison pour traitement de perte osseuse

Non-Patent Citations (59)

* Cited by examiner, † Cited by third party
Title
"<100 pg/ml [11.0 pmol/L] as per KDOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease", AM J KIDNEY DISEASE, vol. 42, 2003, pages S1 - S139
"Clinical practice guidelines for nutrition in chronic renal failure. K/DOQI, National Kidney Foundation", AM J KIDNEY DIS, vol. 35, no. 6, 2000, pages 1 - 140
BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426
BRANDENBURG; FLOEGE, NDT PLUS, vol. 3, 2008, pages 135 - 47
CEJKA DANIEL ET AL: "Renal Elimination of Sclerostin Increases With Declining Kidney Function", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, THE ENDOCRINE SOCIETY, US, vol. 99, no. 1, 1 January 2014 (2014-01-01), pages 248 - 255, XP009178241, ISSN: 0021-972X, DOI: 10.1210/JC.2013-2786 *
CEJKA ET AL., BLOOD PRESS. RES., vol. 33, 2010, pages 221 - 26
CEJKA ET AL., CLIN J AM SOC NEPHROL, vol. 6, 2011, pages 877 - 882
CEJKA ET AL., NEPHROL. DIAL. TRANSPLANT., vol. 0, 2011, pages 1 - 5
CEJKA, KIDNEY BLOOD PRES RES, vol. 33, 2010, pages 221 - 26
CEJKA; HAAS, SEMINARS IN DIALYSIS, vol. 24, 2011, pages 431 - 33
CHRISTIAN FAUL ET AL: "FGF23 induces left ventricular hypertrophy", JOURNAL OF CLINICAL INVESTIGATION, vol. 121, no. 11, 1 November 2011 (2011-11-01), pages 4393 - 4408, XP055065727, ISSN: 0021-9738, DOI: 10.1172/JCI46122 *
COCO ET AL., AM J KIDNEY DIS, vol. 36, no. 6, 2006, pages 1115 - 1121
COEN, J. NEPHROL, vol. 18, 2005, pages 117 - 22
D. CEJKA ET AL: "Sclerostin and Dickkopf-1 in Renal Osteodystrophy", CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol. 6, no. 4, 16 December 2010 (2010-12-16), pages 877 - 882, XP055121511, ISSN: 1555-9041, DOI: 10.2215/CJN.06550810 *
D. CEJKA ET AL: "Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients", NEPHROLOGY DIALYSIS TRANSPLANTATION, vol. 27, no. 1, 25 May 2011 (2011-05-25), pages 226 - 230, XP055121671, ISSN: 0931-0509, DOI: 10.1093/ndt/gfr270 *
DESMOND PADHI ET AL: "Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody", JOURNAL OF BONE AND MINERAL RESEARCH, vol. 26, no. 1, 1 January 2011 (2011-01-01), pages 19 - 26, XP055037191, ISSN: 0884-0431, DOI: 10.1002/jbmr.173 *
DRUEKE; LAFAG-PROUST, CLIN J AM SOC NEPHROL, vol. 6, 2011, pages 700 - 703
ENGELKE ET AL., J OF CLINICAL DENSITOMETRY: ASSESSMENT OF SKELETAL HEALTH, vol. 11, 2008, pages 123 - 162
FAUL ET AL., J CLIN INVEST., vol. 121, 2011, pages 4393 - 4408
FROST ET AL., J BONE MINER RES., vol. 26, 2011, pages 1002 - 11
GOTCH; SARGENT, KIDNEY INT., vol. 28, 1985, pages 526 - 34
HAMPSON GEETA ET AL: "The relationship between inhibitors of the Wnt signalling pathway (Dickkopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal women", BONE, PERGAMON PRESS., OXFORD, GB, vol. 56, no. 1, 20 May 2013 (2013-05-20), pages 42 - 47, XP028675325, ISSN: 8756-3282, DOI: 10.1016/J.BONE.2013.05.010 *
HARRIS, RJ., JOURNAL OF CHROMATOGRAPHY, vol. 705, 1995, pages 129 - 134
HOLLINGER; HUDSON, NATURE BIOTECHNOLOGY, vol. 23, no. 9, 2005, pages 1126 - 1136
HUSTON ET AL., PROC. NATL. ACAD. SCI., vol. 85, 1988, pages 5879 - 5883
JEAN ET AL., NEPHROL DIAL TRANSPLANT, vol. 24, 2009, pages 2792 - 96
KABAT, E. A. ET AL.: "Sequences of Proteins of Immunological Interest", 1991, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, NIH PUBLICATION NO. 91-3242
KELLER; KNEISSEL, BONE, vol. 37, no. 2, 2005, pages 148 - 58
KNAPPIK ET AL., J MOL BIOL, vol. 296, 2000, pages 57 - 86
L. VIAENE ET AL: "Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis?", NEPHROLOGY DIALYSIS TRANSPLANTATION, vol. 28, no. 12, 19 April 2013 (2013-04-19), pages 3024 - 3030, XP055122006, ISSN: 0931-0509, DOI: 10.1093/ndt/gft039 *
LAVI-MOSHAYOFF ET AL., AM J PHYSIOL RENAL PHYSIOL, vol. 299, 2010, pages F882 - F889
LEVEY ET AL., ANN. INTERN. MED., vol. 139, 2003, pages 137 - 147
LI ET AL., J. BONE MINER RES., vol. 24, 2009, pages 578 - 88
LI ET AL., J. BONE MINER. RES., vol. 25, 2010, pages 2371 - 80
LINK, RADIOLOGY, vol. 263, 2012, pages 3 - 17
M. FROST, J. BONE MINER RES., vol. 26, 2011, pages 1002 - 11
MALLUCHE; FAUGERE, KIDNEY INT, vol. 38, 1990, pages 193 - 211
MESSA ET AL., J CLIN ENDOCRINOL METAB., vol. 77, 1993, pages 949 - 55
MESSA ET AL., J. CLIN. ENDOCRINOL. METAB., vol. 77, 1993, pages 949 - 55
MOE ET AL., KIDNEY INTERNATIONAL, vol. 69, 2006, pages 1945 - 53
MOE ET AL.: "KDIGO guideline: Diagnosis of CKD-MBD: biochemical abnormalities", KIDNEY INTERNATIONAL, vol. 76, no. 113, 2009, pages S22 - S49
MOE; CHEN, JASN, vol. 19, 2007, pages 213 - 216
MULLER ET AL., PHUS MED BIOL., vol. 34, 1989, pages 741 - 9
MUYLDERMANS ET AL., TIBS, vol. 24, 2001, pages 230 - 235
OMINSKY ET AL., J. BONE MIN. RES, 2 December 2010 (2010-12-02)
OMINSKY ET AL., J. BONE MINER RES., vol. 25, 2010, pages 948 - 59
PADHI ET AL., J. BONE MINER. RES., vol. 26, 2011, pages 19 - 26
SALUSKY, J. AM SOC NEPHROL, vol. 12, 2001, pages 1978 - 85
SARDIWAL ET AL., KIDNEY INT., vol. 82, no. 1, 2012, pages 100 - 105
SHIMADA ET AL., J BONE MINER RES, vol. 19, 2004, pages 429 - 35
SILVER ET AL., NEPHROL DIAL TRANSPLANT, vol. 27, 2012, pages 1715 - 20
SPASOVSKI ET AL., NEPHROL. DIAL. TRANSPLANT., vol. 18, 2003, pages 1159 - 1166
TANAKA ET AL., NDT PLUS, no. 3, 2008, pages III59 - III62
THAMBIAH S ET AL: "Circulating Sclerostin and Dickkopf-1 (DKK1) in Predialysis Chronic Kidney Disease (CKD): Relationship with Bone Density and Arterial Stiffness", CALCIFIED TISSUE INTERNATIONAL, SPRINGER-VERLAG, NE, vol. 90, no. 6, 21 April 2012 (2012-04-21), pages 473 - 480, XP035053944, ISSN: 1432-0827, DOI: 10.1007/S00223-012-9595-4 *
V. LAVI-MOSHAYOFF ET AL: "PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop", AJP: RENAL PHYSIOLOGY, vol. 299, no. 4, 1 October 2010 (2010-10-01), pages F882 - F889, XP055122050, ISSN: 0363-6127, DOI: 10.1152/ajprenal.00360.2010 *
WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546
WHITE ET AL., NAT GENET, vol. 26, 2000, pages 345 - 48
YAMASHITA ET AL., EUR J. ENDOCRINOL, vol. 151, 2004, pages 55 - 60
ZAPATA ET AL., PROTEIN ENG., vol. 8, no. 10, 1995, pages 1057 - 1062

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108291258A (zh) * 2015-06-04 2018-07-17 Emv梅斯有限公司 诊断和治疗mers相关肾病
CN108291258B (zh) * 2015-06-04 2022-04-08 港大科桥有限公司 诊断和治疗mers相关肾病
WO2019227087A3 (fr) * 2018-05-25 2020-01-02 The Trustees Of Columbia University In The City Of New York Biomarqueurs du type d'ostéodystrophie rénale
WO2021091868A1 (fr) * 2019-11-04 2021-05-14 Regeneron Pharmaceuticals, Inc. Modèle de rongeur à densité minérale osseuse accrue

Similar Documents

Publication Publication Date Title
AU2020294193B2 (en) Anti-pro/latent-Myostatin antibodies and uses thereof
US20230348583A1 (en) TGFbeta1-BINDING IMMUNOGLOBULINS AND USE THEREOF
AU2018201333B2 (en) DKK1 Antibodies And Methods Of Use
JP2022137183A (ja) 抗プロ／潜在型ミオスタチン抗体およびその使用
US11896667B2 (en) Treatment for bone diseases
TWI564305B (zh) 治療性抗體
US9493562B2 (en) Anti-Siglec-15 antibodies
KR102581734B1 (ko) 트랜스타이레틴의 검출 방법
AU2022268305A1 (en) Methods for treating metabolic diseases by inhibiting myostatin activation
WO2014118705A1 (fr) Procédé de traitement des troubles minéraux et osseux de la maladie rénale chronique en utilisant des antagonistes de la sclérostine
EP3404041B1 (fr) Procédé de traitement de l&#39;ostéoporose
US11851483B2 (en) Anti-sclerostin antibodies and their use to treat bone disorders as part of a regimen
CN113950355A (zh) Fgf23的抗体分子和其用途
AU2022357544A1 (en) Methods of using anti-sclerostin antibodies in treatment of osteogenesis imperfecta

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14713903

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14713903

Country of ref document: EP

Kind code of ref document: A1